Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: In type 2 diabetes, tight glycaemic control lowers the risk of diabetic complications, but it remains uncertain whether variability of glycaemia influences outcomes. We examined the association of glycated haemoglobin (HbA 1c) variability with incident chronic kidney disease and cardiovascular disease in a prospective cohort of 8439 Chinese patients with type 2 diabetes recruited from 1994 to 2007. Methods: Intrapersonal mean and SD of serially measured HbA 1c were calculated. Chronic kidney disease was defined as estimated glomerular filtration rate <60 ml/min per 1.73 m 2. Cardiovascular disease was defined as events of ischemic heart disease, heart failure, ischemic stroke or peripheral vascular disease. Results: Over a median follow‐up period of 7.2 years, 19.7 and 10.0% of patients developed chronic kidney disease and cardiovascular disease, respectively. Patients who progressed to chronic kidney disease had higher mean HbA 1c (7.8 ± 1.3% vs 7.4 ± 1.2%, p < 0.001) and SD (1.0 ± 0.8% vs 0.8 ± 0.6%, p < 0.001) than nonprogressors. Similarly, patients who developed cardiovascular disease had higher mean HbA 1c (7.7 ± 1.3% vs 7.4 ± 1.2%, p < 0.001) and SD (1.4 ± 1.1% vs 1.1 ± 0.8%, p < 0.001) than patients who did not develop cardiovascular disease. By using multivariate‐adjusted Cox regression analysis, adjusted SD was associated with incident chronic kidney disease and cardiovascular disease with corresponding hazard ratios of 1.16 (95% CI 1.11–1.22), p < 0.001) and 1.27 (95% CI 1.15–1.40, p < 0.001), independent of mean HbA 1c and other confounding variables. Conclusions: Long‐term glycaemic variability expressed by SD of HbA 1c predicted development of renal and cardiovascular complications. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Ceriello, A., Esposito, K., Piconi, L., Ihnat, M. A., Thorpe, J. E., Testa, R., Boemi, M., & Giugliano, D. (2008) · Diabetes · doi:10.2337/db08-0063 · Cited by 1,310 · cited 2×
“Despite theoretical mechanisms such as oxidative stress and endothelial dysfunction [6,7], previous studies that”
ResultIntensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351 · cited 1×
“following a cardiac event, found no difference in outcome between patients assigned to receive basal insulin and those receiving prandial insulin [20].”
BackgroundNalysnyk, L., Hernandez‐Medina, M., & Krishnarajah, G. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01160.x · Cited by 343
Cited by
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016) · Biomarker Insights · doi:10.4137/bmi.s38440 · Cited by 1,381
Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Gorst, C., Kwok, C. S., Aslam, S., Buchan, I., Kontopantelis, E., Myint, P. K., Heatlie, G., Loke, Y., Rutter, M. K., & Mamas, M. A. (2015) · Diabetes Care · doi:10.2337/dc15-1188 · Cited by 530
Epidemiology of diabetes and diabetic complications in China
Ma, R. C. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4557-7 · Cited by 491
Self-citationCardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222
“As a whole, most agree that glycemic variability predicts all-cause mortality [29, 32, 33, 36–40], fatal or non-fatal cardiovascular diseases [23, 28–32], new microalbuminuria development [16, 18–22, 25] and renal function deterioration [16, 23, 24, 26], although there were opposing reports for these outcomes [19, 29,…”
BackgroundKoye, D. N., Shaw, J. E., Reid, C. M., Atkins, R. C., Reutens, A. T., & Magliano, D. J. (2017) · Diabetic Medicine · doi:10.1111/dme.13324 · Cited by 140
Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial
Zhou, J. J., Schwenke, D. C., Bahn, G., & Reaven, P. (2018) · Diabetes Care · doi:10.2337/dc18-0548 · Cited by 131
“Many studies report adverse effects of glycemic variation, including on renal and cardiovascular complications and all-cause mortality (9,12,14,25,26).”
BackgroundVirk, S. A., Donaghue, K. C., Cho, Y. H., Benitez-Aguirre, P., Hing, S., Pryke, A., Chan, A., & Craig, M. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3604 · Cited by 109
“This latter criterion was instituted as a larger number of HbA1c measurements produce more reliable measures of glycemic variability (2, 7).”
BackgroundScott, E. S., Januszewski, A. S., O’Connell, R., Fulcher, G., Scott, R., Kesaniemi, A., Wu, L., Colagiuri, S., Keech, A., & Jenkins, A. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa361 · Cited by 70
Chen, J., Yi, Q., Wang, Y., Wang, J., Yu, H., Zhang, J., Hu, M., Xu, J., Wu, Z., Hou, L., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110085 · Cited by 69
Hu, Y.-M., Zhao, L.-H., Zhang, X.-L., Cai, H.-L., Huang, H.-Y., Xu, F., Chen, T., Wang, X.-Q., Guo, A.-S., Li, J.-A., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1546-z · Cited by 57
Kaze, A. D., Santhanam, P., Erqou, S., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001753 · Cited by 40
Seferović, P., Farmakis, D., Bayes-Genis, A., Ben Gal, T., Böhm, M., Chioncel, O., Ferrari, R., Filippatos, G., Hill, L., Jankowska, E., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2575 · Cited by 24
Metadata
- Authors
- Luk, A. O. Y., Ma, R. C. W., Lau, E. S. H., Yang, X., Lau, W. W. Y., Yu, L. W. L., Chow, F. C. C., Chan, J. C. N., & So, W.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 29
- Issue
- 5
- Pages
- 384-390
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2138829643
- Cited by
- 146
- References
- 7
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.